IDEC Pharmaceuticals Announces Webcast of Its Annual Meeting

(BUSINESS WIRE) — IDEC Pharmaceuticals Corporation (NASDAQ:IDPH) will webcast its annual meeting on Monday, May 19, 2003, at 6:00 p.m. Eastern Time (3:00 p.m. Pacific Time).

This webcast, hosted by CCBN, can be accessed at IDPH’s website at, where a replay will be archived. For a menu of IDEC’s current news releases and quarterly reports or to retrieve a specific release, call (888) 329-2309.

IDEC Pharmaceuticals Corporation is a leader in the discovery, development, and commercialization of targeted immunotherapies for the treatment of cancer and autoimmune diseases. IDEC discovered and developed the first commercially available radioimmunotherapy product (Zevalin(TM)) approved in the United States, which is used to treat certain types of B-cell non-Hodgkin’s lymphoma. IDEC also discovered and, with co-promotion partner Genentech, Inc., developed the first monoclonal antibody product (Rituxan(R)) approved in the United States for the treatment of cancer. Rituxan is approved in over 70 countries worldwide and is also used to treat various types of B-cell non-Hodgkin’s lymphoma. Based in San Diego, IDEC is an integrated biopharmaceutical company with multiple products in clinical stage development and strategic alliances in a variety of research platforms.

This webcast is also being distributed over CCBN’s Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN’s individual investor center at or by visiting any of the investor sites in CCBN’s Individual Investor Network. Institutional investors can access the call via CCBN’s password-protected event management site, StreetEvents (

CONTACT: IDEC Pharmaceuticals Corporation Vince Reardon, 858/431-8656

SOURCE: IDEC Pharmaceuticals Corporation